ReviewFrontiers in oncology2026
From inflammation to carcinogenesis: MiRNA regulates epithelial-mesenchymal transition to facilitate malignant progression of gastric precancerous lesions.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The process of chronic gastritis transforming into gastric cancer (GC) follows the classic Correa cascade, with persistent inflammation driving the stepwise transition from normal gastric mucosa through superficial gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately carcinoma. Among these stages, intestinal metaplasia and dysplasia occurring on an atrophic mucosal background are widely regarded as the most common gastric precancerous lesions (GPL) because of their pronounced carcinogenic risk. Chronic inflammation can induce epithelial-mesenchymal transition (EMT), thereby accelerating gastric malignant progression. In the GPL stage, the inflammatory gastric microenvironment commonly induces partial EMT (pEMT); importantly, this state is partly reversible and may be amenable to intervention to slow disease progression. As lesions advance, epithelial cells more fully undergo EMT, acquiring greater motility, invasiveness, and metastatic capability, which increases susceptibility to malignant conversion. MicroRNAs (miRNAs) are key molecular regulators in the transition from chronic gastritis to GC through EMT modulation. This review comprehensively discusses inflammation-driven EMT activation and functionally classifies pro-EMT oncomiRNAs (e.g., miR-21, miR-155) and anti-EMT tumor-suppressive miRNAs (e.g., miR-200 family, let-7 family, miR-34a), delineating a complex crosstalk network among inflammation, miRNA, and EMT. We further evaluate miRNAs as non-invasive biomarkers for early detection and prognosis of GPL and discuss emerging therapeutic strategies targeting the miRNA-EMT axis, including nanoparticle- or exosome-based delivery systems, miRNA antagonists, and miRNA sponges. Nevertheless, clinical application of circulating miRNAs remains limited by insufficient assay standardization and validation, incomplete target specificity, off-target effects, suboptimal delivery efficiency, and a lack of large-scale clinical evidence. By integrating molecular mechanisms and transformation status of miRNA-EMT axis in GPL, this review provides new insights for precision prevention and targeted intervention in gastric carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.